TG Therapeutics (NASDAQ:TGTX) Trading Up 4.9% – What’s Next?

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) shot up 4.9% during trading on Tuesday . The stock traded as high as $24.12 and last traded at $23.94. 1,291,632 shares traded hands during trading, a decline of 65% from the average session volume of 3,677,023 shares. The stock had previously closed at $22.83.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on TGTX shares. The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a research note on Wednesday, September 18th. Finally, B. Riley lifted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.83.

TG Therapeutics Stock Performance

The stock has a market capitalization of $3.80 billion, a PE ratio of 106.91 and a beta of 2.21. The business’s fifty day moving average is $22.87 and its two-hundred day moving average is $19.12. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The firm had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. During the same period in the previous year, the firm posted ($0.34) EPS. The business’s quarterly revenue was up 357.0% on a year-over-year basis. As a group, research analysts anticipate that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

Several institutional investors have recently modified their holdings of the stock. NBC Securities Inc. boosted its position in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 485 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in TG Therapeutics in the second quarter worth $35,000. ORG Wealth Partners LLC purchased a new stake in TG Therapeutics in the third quarter worth $53,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of TG Therapeutics during the first quarter valued at $58,000. Finally, nVerses Capital LLC increased its stake in TG Therapeutics by 34.9% in the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 1,500 shares during the period. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.